Literature DB >> 21336703

Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.

Lediana Iagalo Miguel1, Camila B Almeida, Fabiola Traina, Andreia A Canalli, Venina M Dominical, Sara T O Saad, Fernando F Costa, Nicola Conran.   

Abstract

OBJECTIVE: Leukocyte adhesion to vessel walls may initiate vaso-occlusion in sickle cell anemia (SCA); however, the extent to which inflammation participates in this mechanism is not understood. This in vitro study investigated whether inflammatory molecules, commonly augmented in SCA, can affect neutrophil adhesive properties and whether cyclic guanosine monophosphate (cGMP)-elevating agents can inhibit such adhesion. SUBJECTS AND METHODS: Effects of Interleukin 8 (IL-8), tumor necrosis factor-α (TNF-α), granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines, BAY 73-6691 [phosphodiesterase (PDE)-9A-inhibitor], and BAY 41-2271 (guanylate-cylase stimulator) on the adhesive properties of neutrophils from healthy control (CON) and steady-state SCA individuals were determined using static-adhesion assays.
RESULTS: SCA neutrophils demonstrated increased adhesive properties, compared to CON neutrophils; IL-8, TNF-α and GM-CSF increased CON neutrophil adhesion and further increased SCA neutrophil adhesion to fibronectin (FN). The PDE9A inhibitor, BAY-73-6691, significantly reduced basal CON neutrophil and SCA neutrophil adhesion; this was accompanied by decreased SCA neutrophil surface expressions of the L-selectin and CD11b adhesion molecules. BAY-73-6691 also significantly reduced cytokine-stimulated CON neutrophil and SCA neutrophil adhesion to FN; however, this was not accompanied by alterations in adhesion-molecule presentation.
CONCLUSIONS: The chronic inflammatory nature of SCA may contribute to leukocyte adhesive functions in SCA. Furthermore, elevation of leukocyte cGMP may be an interesting approach for inhibition of leukocyte adhesion to the vessel wall, even in the presence of inflammatory stimuli.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336703     DOI: 10.1007/s00011-011-0315-8

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  48 in total

1.  Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition.

Authors:  Erwin Bischoff; Johannes-Peter Stasch
Journal:  Circulation       Date:  2004-09-21       Impact factor: 29.690

2.  Prediction of adverse outcomes in children with sickle cell disease.

Authors:  S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

Review 3.  Hemoglobin disorders and endothelial cell interactions.

Authors:  Nicola Conran; Fernando F Costa
Journal:  Clin Biochem       Date:  2009-07-04       Impact factor: 3.281

4.  Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension.

Authors:  Roberto F Machado; Sabrina Martyr; Gregory J Kato; Robyn J Barst; Anastasia Anthi; Michael R Robinson; Lori Hunter; Wynona Coles; James Nichols; Christian Hunter; Vandana Sachdev; Oswaldo Castro; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

5.  Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque.

Authors:  D English; B R Andersen
Journal:  J Immunol Methods       Date:  1974-08       Impact factor: 2.303

6.  Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion.

Authors:  Eileen M Finnegan; Aslihan Turhan; David E Golan; Gilda A Barabino
Journal:  Am J Hematol       Date:  2007-04       Impact factor: 10.047

7.  Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium.

Authors:  Rahima Zennadi; Ai Chien; Ke Xu; Milena Batchvarova; Marilyn J Telen
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

8.  Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272.

Authors:  Florian Mullershausen; Michael Russwurm; Andreas Friebe; Doris Koesling
Journal:  Circulation       Date:  2004-04-05       Impact factor: 29.690

9.  Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease.

Authors:  Andreia A Canalli; Carla F Franco-Penteado; Fabiola Traina; Sara T O Saad; Fernando F Costa; Nicola Conran
Journal:  Eur J Haematol       Date:  2007-08-03       Impact factor: 2.997

10.  Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.

Authors:  C Lanaro; C F Franco-Penteado; D M Albuqueque; S T O Saad; N Conran; F F Costa
Journal:  J Leukoc Biol       Date:  2008-11-12       Impact factor: 4.962

View more
  8 in total

Review 1.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

Review 2.  Unraveling the Pathogenesis of Asthma and Chronic Obstructive Pulmonary Disease Overlap: Focusing on Epigenetic Mechanisms.

Authors:  Yung-Che Chen; Yu-Ping Chang; Kuo-Tung Huang; Po-Yuan Hsu; Chang-Chun Hsiao; Meng-Chih Lin
Journal:  Cells       Date:  2022-05-24       Impact factor: 7.666

3.  Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

Authors:  Camila Bononi Almeida; Christoph Scheiermann; Jung-Eun Jang; Colette Prophete; Fernando Ferreira Costa; Nicola Conran; Paul S Frenette
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

4.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

5.  A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease.

Authors:  James G McArthur; Niels Svenstrup; Chunsheng Chen; Aurelie Fricot; Caroline Carvalho; Julia Nguyen; Phong Nguyen; Anna Parachikova; Fuad Abdulla; Gregory M Vercellotti; Olivier Hermine; Dave Edwards; Jean-Antoine Ribeil; John D Belcher; Thiago T Maciel
Journal:  Haematologica       Date:  2019-05-30       Impact factor: 9.941

6.  Heme induces significant neutrophil adhesion in vitro via an NFκB and reactive oxygen species-dependent pathway.

Authors:  Lediana I Miguel; Flávia C Leonardo; Lidiane S Torres; Flávia Garcia; Rafaela Mendonça; Wilson A Ferreira; Érica M F Gotardo; Fernanda C Z Fabris; Pamela L Brito; Fernando F Costa; Nicola Conran
Journal:  Mol Cell Biochem       Date:  2021-06-30       Impact factor: 3.396

7.  Biomarkers from circulating neutrophil transcriptomes have potential to detect unruptured intracranial aneurysms.

Authors:  Vincent M Tutino; Kerry E Poppenberg; Lu Li; Hussain Shallwani; Kaiyu Jiang; James N Jarvis; Yijun Sun; Kenneth V Snyder; Elad I Levy; Adnan H Siddiqui; John Kolega; Hui Meng
Journal:  J Transl Med       Date:  2018-12-28       Impact factor: 5.531

8.  The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Ozlem Yildiz; Johannes Schroth; Vittoria Lombardi; Valentina Pucino; Yoana Bobeva; Ping Kei Yip; Klaus Schmierer; Claudio Mauro; Timothy Tree; Sian Mari Henson; Andrea Malaspina
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.